RxDoctor Payments Data

Deniz Garcia de la Rosa, MD

Nephrology · Rio Piedras, PRNPI 1811992712

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,565 of the $3,108 with a category attached, or 82.5%. 17 manufacturers reported payments, led by AstraZeneca at 37.0% of the total.

$3,108in general payments, 2019–2025

Across 67 payments — averaging $46.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Mallinckrodt Hospital Products Inc.$299
  • Cormedix Inc.$261
  • Bayer$195
  • Nxstage Medical, Inc.$171
  • GSK$157
  • plus $874 from 11 others

What the payments were for

  • Travel & lodging$2618%
  • Food & beverage$2,56583%
  • Education$2829%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,108 in reported general payments places this provider in the 75th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$29,310
Medicare patients
32
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate295$60,864
LokelmaSodium Zirconium Cyclosilicate53$26,190
FarxigaDapagliflozin Propanediol30$21,098
EliquisApixaban25$16,069
Calcium Acetate101$11,694
Lanthanum Carbonate26$10,066
Sodium Polystyrene Sulfonate64$7,458
Cinacalcet Hcl36$4,462
Midodrine Hcl59$2,844
SynthroidLevothyroxine Sodium26$1,791
Calcitriol91$1,467
Spironolactone142$1,305
Candesartan Cilexetil11$924
Nifedipine ErNifedipine39$730
Hydralazine Hcl30$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$1,151$47,28783 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →